Neurotrack Closes $6.5 Million In Fresh Funding, Launches Flagship Cognitive Assessment

image

Palo Alto-based digital health startup Neurotrack announces that it has raised a $6.5 million Series B funding round led by Khosla Ventures, with additional investments from AME Cloud Ventures, ISeed Ventures, and returning investors Social Capital and Founders Fund. The new funding brings Neurotrack’s lifetime funding level to $9.5 million since its 2012 formation. The company started out in Boston, and was a member of the Boston-based Rock Health incubator program in the spring of 2012 before moving its headquarters to California.

Since its formation, Neurotrack has been working to develop a cognitive assessment tool that can accurately diagnose Alzheimer’s disease and mild cognitive impairment by displaying on-screen pictures to the patient and then analyzing their eye movements while they look over the images. Developers pair images on the screen so that one is familiar to the patient, while the second is unfamiliar. Next, a camera tracks the patient’s eye movement and eye fixation to measure which images the patients are focusing on longer. Then, percentages for how much of the total time the patient spent focused on both the familiar and unfamiliar image were calculated. This information is then used to detect abnormalities in the hippocampus that are unique to Alzheimer’s disease and mild cognitive impairment. Because the hippocampus is the first part of the brain that is affected by these conditions, researchers using the new tool were able to accurately diagnose the conditions as early as six years before any signs or symptoms presented. Currently, there is no reliable screening for early-onset Alzheimer’s disease, but treatment is far more effective in patients who are diagnosed early. Neurotrack’s diagnostic test takes just five minutes to administer, and because of this, the company hopes to see it incorporated into standard preventative screenings for at-risk populations across the US.

In addition to announcing its fresh funding, the company also unveiled its flagship cognitive assessment, announcing that it would be available to physicians starting in 2016. The fresh capital will be used to ramp up for the launch. It will also be used to fund a clinical trial for its second product, a cognitive health program that makes lifestyle, diet, exercise, and sleep recommendations that collectively have “been shown to prevent decline and improve cognitive scores in people at risk for impairment.”


Enjoy HIStalk Connect? Sign up for update alerts, or follow us at @HIStalkConnect.

↑ Back to top

Founding Sponsors

Platinum Sponsors